Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer

Hedde D. Biesma, Philip C. Schouten, Miangela M. Lacle, Joyce Sanders, Wim Brugman, Ron Kerkhoven, Ingrid Mandjes, Petra van der Groep, Paul J. van Diest, Sabine C. Linn

Research output: Contribution to journalArticle

Abstract

Genomic aberrations can be used to subtype breast cancer. In this study, we investigated DNA copy number (CN) profiles of 69 cases of male breast cancer (MBC) by array comparative genomic hybridization (aCGH) to detect recurrent gains and losses in comparison with female breast cancers (FBC). Further, we classified these profiles as BRCA1-like, BRCA2-like or non-BRCA-like profiles using previous classifiers derived from FBC, and correlated these profiles with pathological characteristics. We observed large CN gains on chromosome arms 1q, 5p, 8q, 10p, 16p, 17q, and chromosomes 20 and X. Large losses were seen on chromosomes/chromosome arms 1p, 6p, 8p, 9, 11q, 13, 14q, 16q, 17p, and 22. The pattern of gains and losses in estrogen receptor positive (ER+) MBC was largely similar to ER+ FBC, except for gains on chromosome X in MBC, which were uncommon in FBC. Out of 69 MBC patients, 15 patients (22%) had a BRCA2-like profile, of which 2 (3%) were also BRCA1-like. One patient (1%) was only BRCA1-like; the remaining 53 (77%) patients were classified as non-BRCA-like. BRCA2-like cases were more often p53 accumulated than non-BRCA-like cases (P=0.014). In conclusion, the pattern of gains and losses in ER+ MBC was largely similar to that of its ER+ FBC counterpart, except for gains on chromosome X in MBC, which are uncommon in FBC. A significant proportion of MBC has a BRCA2-like aCGH profile, pointing to a potentially hereditary nature, and indicating that they could benefit from a drug regimen targeting BRCA defects as in FBC.

Original languageEnglish (US)
Pages (from-to)734-744
Number of pages11
JournalGenes Chromosomes and Cancer
Volume54
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Male Breast Neoplasms
Comparative Genomic Hybridization
Breast Neoplasms
Chromosomes
X Chromosome
Chromosomes, Human, Pair 20
Drug Delivery Systems
Estrogen Receptors
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Biesma, H. D., Schouten, P. C., Lacle, M. M., Sanders, J., Brugman, W., Kerkhoven, R., ... Linn, S. C. (2015). Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer. Genes Chromosomes and Cancer, 54(12), 734-744. https://doi.org/10.1002/gcc.22284

Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer. / Biesma, Hedde D.; Schouten, Philip C.; Lacle, Miangela M.; Sanders, Joyce; Brugman, Wim; Kerkhoven, Ron; Mandjes, Ingrid; van der Groep, Petra; van Diest, Paul J.; Linn, Sabine C.

In: Genes Chromosomes and Cancer, Vol. 54, No. 12, 01.12.2015, p. 734-744.

Research output: Contribution to journalArticle

Biesma, HD, Schouten, PC, Lacle, MM, Sanders, J, Brugman, W, Kerkhoven, R, Mandjes, I, van der Groep, P, van Diest, PJ & Linn, SC 2015, 'Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer', Genes Chromosomes and Cancer, vol. 54, no. 12, pp. 734-744. https://doi.org/10.1002/gcc.22284
Biesma, Hedde D. ; Schouten, Philip C. ; Lacle, Miangela M. ; Sanders, Joyce ; Brugman, Wim ; Kerkhoven, Ron ; Mandjes, Ingrid ; van der Groep, Petra ; van Diest, Paul J. ; Linn, Sabine C. / Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer. In: Genes Chromosomes and Cancer. 2015 ; Vol. 54, No. 12. pp. 734-744.
@article{08b99a41f56c4b4e8807b7a739191bfe,
title = "Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer",
abstract = "Genomic aberrations can be used to subtype breast cancer. In this study, we investigated DNA copy number (CN) profiles of 69 cases of male breast cancer (MBC) by array comparative genomic hybridization (aCGH) to detect recurrent gains and losses in comparison with female breast cancers (FBC). Further, we classified these profiles as BRCA1-like, BRCA2-like or non-BRCA-like profiles using previous classifiers derived from FBC, and correlated these profiles with pathological characteristics. We observed large CN gains on chromosome arms 1q, 5p, 8q, 10p, 16p, 17q, and chromosomes 20 and X. Large losses were seen on chromosomes/chromosome arms 1p, 6p, 8p, 9, 11q, 13, 14q, 16q, 17p, and 22. The pattern of gains and losses in estrogen receptor positive (ER+) MBC was largely similar to ER+ FBC, except for gains on chromosome X in MBC, which were uncommon in FBC. Out of 69 MBC patients, 15 patients (22{\%}) had a BRCA2-like profile, of which 2 (3{\%}) were also BRCA1-like. One patient (1{\%}) was only BRCA1-like; the remaining 53 (77{\%}) patients were classified as non-BRCA-like. BRCA2-like cases were more often p53 accumulated than non-BRCA-like cases (P=0.014). In conclusion, the pattern of gains and losses in ER+ MBC was largely similar to that of its ER+ FBC counterpart, except for gains on chromosome X in MBC, which are uncommon in FBC. A significant proportion of MBC has a BRCA2-like aCGH profile, pointing to a potentially hereditary nature, and indicating that they could benefit from a drug regimen targeting BRCA defects as in FBC.",
author = "Biesma, {Hedde D.} and Schouten, {Philip C.} and Lacle, {Miangela M.} and Joyce Sanders and Wim Brugman and Ron Kerkhoven and Ingrid Mandjes and {van der Groep}, Petra and {van Diest}, {Paul J.} and Linn, {Sabine C.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1002/gcc.22284",
language = "English (US)",
volume = "54",
pages = "734--744",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer

AU - Biesma, Hedde D.

AU - Schouten, Philip C.

AU - Lacle, Miangela M.

AU - Sanders, Joyce

AU - Brugman, Wim

AU - Kerkhoven, Ron

AU - Mandjes, Ingrid

AU - van der Groep, Petra

AU - van Diest, Paul J.

AU - Linn, Sabine C.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Genomic aberrations can be used to subtype breast cancer. In this study, we investigated DNA copy number (CN) profiles of 69 cases of male breast cancer (MBC) by array comparative genomic hybridization (aCGH) to detect recurrent gains and losses in comparison with female breast cancers (FBC). Further, we classified these profiles as BRCA1-like, BRCA2-like or non-BRCA-like profiles using previous classifiers derived from FBC, and correlated these profiles with pathological characteristics. We observed large CN gains on chromosome arms 1q, 5p, 8q, 10p, 16p, 17q, and chromosomes 20 and X. Large losses were seen on chromosomes/chromosome arms 1p, 6p, 8p, 9, 11q, 13, 14q, 16q, 17p, and 22. The pattern of gains and losses in estrogen receptor positive (ER+) MBC was largely similar to ER+ FBC, except for gains on chromosome X in MBC, which were uncommon in FBC. Out of 69 MBC patients, 15 patients (22%) had a BRCA2-like profile, of which 2 (3%) were also BRCA1-like. One patient (1%) was only BRCA1-like; the remaining 53 (77%) patients were classified as non-BRCA-like. BRCA2-like cases were more often p53 accumulated than non-BRCA-like cases (P=0.014). In conclusion, the pattern of gains and losses in ER+ MBC was largely similar to that of its ER+ FBC counterpart, except for gains on chromosome X in MBC, which are uncommon in FBC. A significant proportion of MBC has a BRCA2-like aCGH profile, pointing to a potentially hereditary nature, and indicating that they could benefit from a drug regimen targeting BRCA defects as in FBC.

AB - Genomic aberrations can be used to subtype breast cancer. In this study, we investigated DNA copy number (CN) profiles of 69 cases of male breast cancer (MBC) by array comparative genomic hybridization (aCGH) to detect recurrent gains and losses in comparison with female breast cancers (FBC). Further, we classified these profiles as BRCA1-like, BRCA2-like or non-BRCA-like profiles using previous classifiers derived from FBC, and correlated these profiles with pathological characteristics. We observed large CN gains on chromosome arms 1q, 5p, 8q, 10p, 16p, 17q, and chromosomes 20 and X. Large losses were seen on chromosomes/chromosome arms 1p, 6p, 8p, 9, 11q, 13, 14q, 16q, 17p, and 22. The pattern of gains and losses in estrogen receptor positive (ER+) MBC was largely similar to ER+ FBC, except for gains on chromosome X in MBC, which were uncommon in FBC. Out of 69 MBC patients, 15 patients (22%) had a BRCA2-like profile, of which 2 (3%) were also BRCA1-like. One patient (1%) was only BRCA1-like; the remaining 53 (77%) patients were classified as non-BRCA-like. BRCA2-like cases were more often p53 accumulated than non-BRCA-like cases (P=0.014). In conclusion, the pattern of gains and losses in ER+ MBC was largely similar to that of its ER+ FBC counterpart, except for gains on chromosome X in MBC, which are uncommon in FBC. A significant proportion of MBC has a BRCA2-like aCGH profile, pointing to a potentially hereditary nature, and indicating that they could benefit from a drug regimen targeting BRCA defects as in FBC.

UR - http://www.scopus.com/inward/record.url?scp=84944280194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944280194&partnerID=8YFLogxK

U2 - 10.1002/gcc.22284

DO - 10.1002/gcc.22284

M3 - Article

VL - 54

SP - 734

EP - 744

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 12

ER -